Precision BioSciences (NASDAQ:DTIL) CFO Sells $31,292.16 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly sold 8,149 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $31,292.16. Following the sale, the chief financial officer owned 125,883 shares of the company’s stock, valued at approximately $483,390.72. This represents a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

John Alexander Kelly also recently made the following trade(s):

• On Wednesday, January 21st, John Alexander Kelly sold 15,213 shares of Precision BioSciences stock. The shares were sold at an average price of $4.03, for a total value of $61,308.39.

Precision BioSciences Stock Up 1.8%

Shares of DTIL traded up $0.07 during midday trading on Thursday, reaching $3.92. 214,558 shares of the company were exchanged, compared to its average volume of 225,532. Precision BioSciences, Inc. has a 1-year low of $3.53 and a 1-year high of $8.82. The stock has a 50-day moving average price of $4.16 and a 200-day moving average price of $5.01. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The company has a market cap of $89.77 million, a price-to-earnings ratio of -0.47 and a beta of 1.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Precision BioSciences currently has a consensus rating of “Hold” and an average price target of $60.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. HBK Sorce Advisory LLC acquired a new stake in shares of Precision BioSciences in the 4th quarter valued at about $38,000. Engineers Gate Manager LP bought a new stake in Precision BioSciences in the fourth quarter valued at about $43,000. Occudo Quantitative Strategies LP bought a new stake in Precision BioSciences in the fourth quarter valued at about $52,000. Miller Financial Services LLC raised its stake in Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after buying an additional 5,000 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Precision BioSciences during the 3rd quarter worth approximately $72,000. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.